We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ASH18

News List

ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab fiercebiotech
January 03, 2019
As the biggest and brightest in the blood cancer world came together for the ASH conference this weekend, European biotech Argenx was busy making a big biobucks deal......
ASH18: New data can’t lift Bluebird Bio’s depressed shares fiercebiotech
January 03, 2019
Bluebird Bio has been singing the praises of two new therapies at the annual American Society of Hematology, but although the data look solid so far, investors don’t seem to be fully on board with the program.......
ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field fiercebiotech
January 02, 2019
This year’s ASH saw a plethora of presentations on BCMA-targeting drugs, but analysts at Jefferies say Bluebird Bio’s CAR-T therapy bb2121 “is still leading the pack.”....
Celgene scores at ASH18 with double luspatercept data pharmaphorum
December 04, 2018
A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019......